Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $68.7 million.

  • Voyager Therapeutics' Non-Current Assets rose 30.66% to $68.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 30.66%. This contributed to the annual value of $116.2 million for FY2024, which is 267.89% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Non-Current Assets is $68.7 million, which was down 27.05% from $94.2 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Non-Current Assets ranged from a high of $116.2 million in Q4 2024 and a low of $31.6 million during Q4 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $54.7 million (2024), whereas its average is $62.4 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 39.32% in 2022, then spiked by 267.89% in 2024.
  • Voyager Therapeutics' Non-Current Assets (Quarterly) stood at $57.2 million in 2021, then slumped by 39.02% to $34.9 million in 2022, then declined by 9.35% to $31.6 million in 2023, then soared by 267.89% to $116.2 million in 2024, then spiked by 30.66% to $68.7 million in 2025.
  • Its last three reported values are $68.7 million in Q3 2025, $94.2 million for Q2 2025, and $108.0 million during Q1 2025.